|
1
|
Church TR, Black WC, Aberle DR, Berg CD,
Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC,
et al National Lung Screening Trial Research Team: Results of
initial low-dose computed tomographic screening for lung cancer. N
Engl J Med. 368:1980–1991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saghir Z, Dirksen A, Ashraf H, Bach KS,
Brodersen J, Clementsen PF, Døssing M, Hansen H, Kofoed KF, Larsen
KR, et al: CT screening for lung cancer brings forward early
disease. The randomised Danish Lung Cancer Screening Trial: Status
after five annual screening rounds with low-dose CT. Thorax.
67:296–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Das M, Riess JW, Frankel P, Schwartz E,
Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, et al: ERCC1
expression in circulating tumor cells (CTCs) using a novel
detection platform correlates with progression-free survival (PFS)
in patients with metastatic non-small-cell lung cancer (NSCLC)
receiving platinum chemotherapy. Lung Cancer. 77:421–426. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Minegishi Y, Inoue A,
Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T,
Isobe H, et al: First-line gefitinib in patients aged 75 or older
with advanced non-small cell lung cancer harboring epidermal growth
factor receptor mutations: NEJ 003 study. J Thorac Oncol.
7:1417–1422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Warth A, Muley T, Meister M, Stenzinger A,
Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and
Weichert W: The novel histologic International Association for the
Study of Lung Cancer/American Thoracic Society/European Respiratory
Society classification system of lung adenocarcinoma is a
stage-independent predictor of survival. J Clin Oncol.
30:1438–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wynes MW, Hinz TK, Gao D, Martini M, Marek
LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al:
FGFR1 mRNA and protein expression, not gene copy number, predict
FGFR TKI sensitivity across all lung cancer histologies. Clin
Cancer Res. 20:3299–3309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laurila N and Koivunen JP: EGFR inhibitor
and chemotherapy combinations for acquired TKI resistance in
EGFR-mutant NSCLC models. Med Oncol. 32:2052015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, et al: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyauchi E, Inoue A, Kobayashi K, Maemondo
M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, et
al North-East Japan Study Group: Efficacy of chemotherapy after
first-line gefitinib therapy in EGFR mutation-positive advanced
non-small cell lung cancer-data from a randomized Phase III study
comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn
J Clin Oncol. 45:670–676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kosaka T, Yamaki E, Mogi A and Kuwano H:
Mechanisms of resistance to EGFR TKIs and development of a new
generation of drugs in non-small-cell lung cancer. J Biomed
Biotechnol. 2011:1652142011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou
Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, et al: Clinical modes of
EGFR tyrosine kinase inhibitor failure and subsequent management in
advanced non-small cell lung cancer. Lung Cancer. 79:33–39. 2013.
View Article : Google Scholar
|
|
14
|
Nurwidya F, Takahashi F, Murakami A and
Takahashi K: Epithelial mesenchymal transition in drug resistance
and metastasis of lung cancer. Cancer Res Treat. 44:151–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stadler SC, Vincent CT, Fedorov VD,
Patsialou A, Cherrington BD, Wakshlag JJ, Mohanan S, Zee BM, Zhang
X, Garcia BA, et al: Dysregulation of PAD4-mediated citrullination
of nuclear GSK3β activates TGF-β signaling and induces
epithelial-to-mesenchymal transition in breast cancer cells. Proc
Natl Acad Sci USA. 110:11851–11856. 2013. View Article : Google Scholar
|
|
17
|
Ham A, Rabadi M, Kim M, Brown KM, Ma Z,
D'Agati V and Lee HT: Peptidyl arginine deiminase-4 activation
exacerbates kidney ischemia-reperfusion injury. Am J Physiol Renal
Physiol. 307:F1052–F1062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baka Z, Barta P, Losonczy G, Krenács T,
Pápay J, Szarka E, Sármay G, Babos F, Magyar A, Géher P, et al:
Specific expression of PAD4 and citrullinated proteins in lung
cancer is not associated with anti-CCP antibody production. Int
Immunol. 23:–414. 4052011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patki M, Chari V, Sivakumaran S, Gonit M,
Trumbly R and Ratnam M: The ETS domain transcription factor ELK1
directs a critical component of growth signaling by the androgen
receptor in prostate cancer cells. J Biol Chem. 288:11047–11065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Senecal A, Munsky B, Proux F, Ly N, Braye
FE, Zimmer C, Mueller F and Darzacq X: Transcription factors
modulate c-Fos transcriptional bursts. Cell Rep. 8:75–83. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang R, Wang J, Ma S, Huang Z and Zhang
G: Requirement of Osteopontin in the migration and protection
against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901
cells. BMC Cell Biol. 12:112011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Obacz J, Takacova M, Brychtova V, Dobes P,
Pastorekova S, Vojtesek B and Hrstka R: The role of AGR2 and AGR3
in cancer: Similar but not identical. Eur J Cell Biol. 94:139–147.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bicker KL and Thompson PR: The protein
arginine deiminases: Structure, function, inhibition, and disease.
Biopolymers. 99:155–163. 2013. View Article : Google Scholar
|
|
24
|
Eades G, Yao Y, Yang M, Zhang Y, Chumsri S
and Zhou Q: miR-200a regulates SIRT1 expression and epithelial to
mesenchymal transition (EMT)-like transformation in mammary
epithelial cells. J Biol Chem. 286:25992–26002. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saitoh M, Shirakihara T and Miyazono K:
Regulation of the stability of cell surface E-cadherin by the
proteasome. Biochem Biophys Res Commun. 381:560–565. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cavallaro U, Schaffhauser B and
Christofori G: Cadherins and the tumour progression: Is it all in a
switch? Cancer Lett. 176:123–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Q, Hou X, Xia J, Qian X, Miele L,
Sarkar FH and Wang Z: Emerging roles of PDGF-D in EMT progression
during tumorigenesis. Cancer Treat Rev. 39:640–646. 2013.
View Article : Google Scholar :
|
|
28
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Field JK, Oudkerk M, Pedersen JH and Duffy
SW: Prospects for population screening and diagnosis of lung
cancer. Lancet. 382:732–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu YH, Mei JS and Zhou J: Randomized study
of gefitinib versus pemetrexed as maintenance treatment in patients
with advanced glandular non-small cell lung cancer. Int J Clin Exp
Med. 8:6242–6246. 2015.PubMed/NCBI
|
|
31
|
Chaft JE, Rekhtman N, Ladanyi M and Riely
GJ: ALK-rearranged lung cancer: Adenosquamous lung cancer
masquerading as pure squamous carcinoma. J Thorac Oncol. 7:768–769.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wagner S, Stuttmann J, Rietz S, Guerois R,
Brunstein E, Bautor J, Niefind K and Parker JE: Structural basis
for signaling by exclusive EDS1 heteromeric complexes with SAG101
or PAD4 in plant innate immunity. Cell Host Microbe. 14:619–630.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chevigny M, Guérin-Montpetit K, Vargas A,
Lefebvre-Lavoie J and Lavoie JP: Contribution of SRF, Elk-1, and
myocardin to airway smooth muscle remodeling in heaves, an
asthma-like disease of horses. Am J Physiol Lung Cell Mol Physiol.
309:L37–L45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Neeb A, Wallbaum S, Novac N,
Dukovic-Schulze S, Scholl I, Schreiber C, Schlag P, Moll J, Stein U
and Sleeman JP: The immediate early gene Ier2 promotes tumor cell
motility and metastasis, and predicts poor survival of colorectal
cancer patients. Oncogene. 31:3796–3806. 2012. View Article : Google Scholar
|
|
37
|
Kawahara T, Shareef HK, Aljarah AK, Ide H,
Li Y, Kashiwagi E, Netto GJ, Zheng Y and Miyamoto H: ELK1 is
up-regulated by androgen in bladder cancer cells and promotes tumor
progression. Oncotarget. 6:29860–29876. 2015.PubMed/NCBI
|
|
38
|
Nieto MA: Epithelial plasticity: A common
theme in embryonic and cancer cells. Science. 342:12348502013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated
colorectal cancer invasion and metastasis. J Clin Invest.
124:1853–1867. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kong D, Li Y, Wang Z and Sarkar FH: Cancer
stem cells and epithelial-to-mesenchymal transition
(EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel).
3:716–729. 2011. View Article : Google Scholar
|
